We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Since its establishment, Zhejiang Saikai Pharmaceutical Technology Co., Ltd. has continuously enhanced its resource integration ability around the pharmaceutical industry chain, built an enterprise-oriented and market-oriented business system, actively identified the key links of the upstream and downstream of the industrial chain, and promoted the overall improvement of the supply chain.
The company has always been committed to opening the international market for small and medium-sized production enterprises. Through the efforts of professional international business team, the company has helped steroid hormone apis and intermediates gain a certain market voice in India. Based on the existing achievements, the company insists on expanding the product line, and has established cooperative relations with many manufacturers in Zhejiang, Hunan, Jiangsu and other provinces. In addition to India, the products are exported to Europe, South America and other overseas regions, and a broad sales market has been established.
Since 2023, relying on the head office to carry out API import, registration and agent procurement business. Under the cooperation of the total company registration team, the company successfully completed the introduction and registration of a number of high-quality apis, and established product cooperation with foreign first-line enterprises, and successfully helped the parent company and domestic pharmaceutical customers related review.
In the future, Sikai Pharmaceutical will forge ahead, do not slack, focus on improving the level of business, to create an excellent corporate brand image. We will make full use of our own advantages, continue to integrate domestic and foreign resources, through strategic cooperation to reach a strong alliance between enterprises, to achieve mutual benefit, mutual assistance and win-win.
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
![(E)-6-Nitro-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole](https://eimg.pharmasources.com/img_Cphi_en/Product/2018_07/Mimg_1807160304633031.JPG!145)
